Floatz logo

Ibrutinib

Symptomatic COVID-19 Infection Laboratory-Confirmed

Academic and Community Cancer Research UnitedSmall moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Symptomatic COVID-19 Infection Laboratory-Confirmed cohort.

Asset / SponsorPhaseRating
Lopinavir
OHSU Knight Cancer Institute
Phase 2CCC
RITONAVIR
OHSU Knight Cancer Institute
Phase 2CCC
Leflunomide
City of Hope Medical Center
Phase 1/2CCC
INTERFERON ALFA-2B
Roswell Park Cancer Institute
Phase 1/2CCC
Rintatolimod
Roswell Park Cancer Institute
Phase 1/2CC
Sars-Cov-2 Antigen-Specific Cytotoxic T-Lymphocytes
M.D. Anderson Cancer Center
Early Phase 1CC

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →